In line with evidence accrued in patients with T2D, incretin-based therapies produced a favorable effect on traditional cardiovascular risk factors, such as lipids and blood pressure, and even reduced the risk of major cardiovascular events and heart failure-related events in individuals with obesity, as recently demonstrated for the first time in the SELECT trial with semaglutide 2.4 mg once-weekly
It is important to fully understand how GLP-1 and GLP-1/GIP receptor agonists impact anesthetic management to provide high quality office-based anesthesia care
In obese and insulin-resistant mice, activation of this system improved glucose tolerance by increasing insulin secretion and action
If you are taking a GLP-1, it is smart to coordinate with your prescribing clinician, especially if you have diabetes, a history of low blood sugar, digestive side effects, or other medical concerns
Weeks 9-12: 8 mg per week (160 units, requires 2 draws from 1 mL syringe or a larger syringe) The 8 mg dose is where retatrutide separates from the competition
Patients should maintain adequate hydration, and those with pre-existing renal impairment should be monitored carefully